BRIEF published on 04/30/2025 at 07:35, 1 year 6 months ago Nicox publie ses résultats financiers pour l'année 2024 Perte Nette Réserves De Trésorerie Résultats Financiers De Nicox Vente De Revenus De VYZULTA Essais NCX 470
PRESS RELEASE published on 04/30/2025 at 07:30, 1 year 6 months ago Nicox Provides Full Year 2024 Financial Results Nicox reports €7.9 million revenue for 2024 with exceptional income of €13.7 million from VYZULTA transfer. Cash of €10.5 million and NCX 470 Phase 3 trial results expected in Q3 2025 Financial Results Revenue Nicox NCX 470 VYZULTA
PRESS RELEASE published on 04/30/2025 at 07:30, 1 year 6 months ago Nicox : Résultats financiers de l’année 2024 Nicox annonce résultats financiers 2024, incluant CA de 7,9M€, produits exceptionnels de 13,7M€ et trésorerie de 10,5M€. Études cliniques NCX 470 en cours Résultats Financiers Trésorerie Études Cliniques Nicox NCX 470
BRIEF published on 03/19/2025 at 07:35, 1 year 7 months ago Nicox Completes Final Visit for NCX 470 Phase 3b Whistler Glaucoma Trial Glaucoma Nicox Clinical Results NCX 470 Phase 3b Trial
BRIEF published on 03/19/2025 at 07:35, 1 year 7 months ago Nicox a terminé la dernière visite de l'essai de phase 3b NCX 470 sur le glaucome à Whistler Nicox Résultats Cliniques NCX 470 Glaucome Essai De Phase 3b
PRESS RELEASE published on 03/19/2025 at 07:30, 1 year 7 months ago Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Nicox completes final patient visits in Phase 3b Whistler Glaucoma Trial for NCX 470, with results expected May 2025. Denali trial in progress, results planned for Q3 2025 Clinical Development Nicox NCX 470 Phase 3b Glaucoma Trial
PRESS RELEASE published on 03/19/2025 at 07:30, 1 year 7 months ago Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Nicox annonce la fin de la visite du dernier patient dans l'étude de phase 3b Whistler sur le NCX 470 pour le glaucome. Résultats attendus en mai 2025 Étude Clinique Nicox NCX 470 Glaucome Phase 3b
BRIEF published on 01/28/2025 at 07:35, 1 year 9 months ago Nicox : Participation aux Grands Congrès en 2025 Investissement Ophtalmologie Congrès Nicox NCX 470
BRIEF published on 01/28/2025 at 07:35, 1 year 9 months ago Nicox: Participation in Major Congresses in 2025 Investment Ophthalmology Congress Nicox NCX 470
PRESS RELEASE published on 01/28/2025 at 07:30, 1 year 9 months ago Nicox : Présentation Scientifique et Participation aux Congrès du premier semestre 2025 Nicox annonce sa participation à des congrès internationaux en ophtalmologie et finance au premier semestre 2025, y compris l'AGS 2025 Congrès Annuel Finance Ophtalmologie Congrès Nicox AGS 2025
Published on 11/06/2026 at 22:15, 2 days 9 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 18 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 18 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 18 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/09/2026 at 07:10, 19 minutes ago Hypoport delivers solid gross profit growth and an increase in EBIT in the first nine months of 2026
Published on 11/09/2026 at 07:00, 29 minutes ago Sandoz launches new semaglutide treatment option in Brazil, expanding patient access to GLP-1 medicine in key global market
Published on 11/09/2026 at 07:00, 29 minutes ago Cicor receives awards for two major defence programmes
Published on 11/09/2026 at 01:55, 5 hours 34 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Statement by Goodman Group & Digital Realty
Published on 11/08/2026 at 12:10, 19 hours 18 minutes ago GSMA MWC26 Doha opens with call to align on global industry standards and close MENA's connectivity gap
Published on 11/09/2026 at 07:00, 29 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 29 minutes ago BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 29 minutes ago Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 29 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 12 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
